Rhumbline Advisers Aeglea Bio Therapeutics, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$0.5 - $2.66 $24,459 - $130,121	-48,918 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$1.87 - $4.77 $9,350 - $23,849	-5,000 Reduced 9.27%	48,918 $113,000
Q4 2021 Feb 10, 2022	SELL	$3.5 - $8.42 $787 - $1,894	-225 Reduced 0.42%	53,918 $256,000
Q3 2021 Nov 12, 2021	BUY	$6.03 - $7.95 $8,900 - $11,734	1,476 Added 2.8%	54,143 $430,000
Q2 2021 Aug 05, 2021	BUY	$6.32 - $8.38 $40,037 - $53,087	6,335 Added 13.67%	52,667 $367,000
Q1 2021 May 06, 2021	SELL	$6.76 - $8.57 $22,781 - $28,880	-3,370 Reduced 6.78%	46,332 $367,000
Q4 2020 Feb 10, 2021	BUY	$7.02 - $9.83 $30,712 - $43,006	4,375 Added 9.65%	49,702 $391,000
Q3 2020 Nov 12, 2020	SELL	$6.51 - $9.33 $40,362 - $57,846	-6,200 Reduced 12.03%	45,327 $321,000
Q2 2020 Aug 13, 2020	BUY	$4.01 - $11.04 $54,435 - $149,868	13,575 Added 35.77%	51,527 $477,000
Q1 2020 May 06, 2020	BUY	$3.51 - $8.48 $1,649 - $3,985	470 Added 1.25%	37,952 $177,000
Q4 2019 Feb 05, 2020	BUY	$7.23 - $8.55 $1,236 - $1,462	171 Added 0.46%	37,482 $286,000
Q3 2019 Oct 23, 2019	BUY	$6.42 - $9.0 $18,829 - $26,397	2,933 Added 8.53%	37,311 $287,000
Q2 2019 Aug 14, 2019	BUY	$6.1 - $8.78 $62,512 - $89,977	10,248 Added 42.47%	34,378 $235,000
Q1 2019 May 01, 2019	BUY	$7.6 - $9.4 $19,448 - $24,054	2,559 Added 11.86%	24,130 $194,000
Q4 2018 Jan 31, 2019	BUY	$6.51 - $10.19 $46,019 - $72,033	7,069 Added 48.75%	21,571 $162,000
Q3 2018 Nov 07, 2018	SELL	$8.24 - $11.0 $6,023 - $8,041	-731 Reduced 4.8%	14,502 $139,000
Q2 2018 Aug 06, 2018	BUY	$7.87 - $10.89 $119,883 - $165,887	15,233 New	15,233 $161,000

Others Institutions Holding AGLE

# of Institutions

Shares Held

241K

Call Options Held

Put Options Held

Abingworth LLP London, X0

241K
Shares

$6.65 Million
0.04% of portfolio

View Full List

About Aeglea BioTherapeutics, Inc.

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

More about AGLE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account